The Patent Finder

Terms ending in 2039

Indi Molecular, Inc.

Every in-force patent on Indi Molecular, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,884,707Compositions for Detection, Inhibition and Imaging of Indoleamine 2, 3-Dioxygenase 1 (IDO1) and Methods of Making and Using Same
In force
 · High confidence
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
US 12,594,350CD8-SPECIFIC Capture Agents, Compositions, and Methods of Using and Making
In force
 · High confidence
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
US 11,919,972Peptide Libraries with Non-Canonical Amino Acids
In force
 · High confidence
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
US 11,638,764Theranostic Capture Agents, Compositions, and Methods of Using and Making
In force
 · High confidence
Indi Molecular, Inc.In forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Indi Molecular, Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited